Lv5
916 积分 2021-09-02 加入
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
4小时前
已完结
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
13小时前
已完结
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
14小时前
待确认
Overall survival in the OlympiA phase III trial of adjuvant olaparib
16小时前
待确认
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
16小时前
待确认
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer (ASCENT-03)
2天前
已完结
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2天前
已完结
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2天前
已完结
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
2天前
已完结
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2天前
已完结
皖公网安备34019202002308
